0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > CEACAM-5

CEACAM-5

Brief Information

Name:Carcinoembryonic antigen related cell adhesion molecule 5
Target Synonym:CEA Cell Adhesion Molecule 5,CEACAM5,Meconium antigen 100,CEA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 5,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5,Carcinoembryonic Antigen,CD66e Antigen,CD66e
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Cat . Non Espèces Description du produit Structure Pureté Caractéristique
CE5-R52H3 Rhesus macaque Rhesus macaque CEACAM-5 / CD66e Protein, His Tag (MALS verified)
CE5-R52H3-structure
CE5-R52H3-sds
CE5-H82E4 Human Biotinylated Human CEACAM-5 / CD66e (593-675) Protein, His,Avitag™ (MALS verified)
CE5-H82E4-structure
CE5-H82E4-sds
CE5-H82E3 Human Biotinylated Human CEACAM-5 / CD66e (499-685) Protein, His,Avitag™ (MALS verified)
CE5-H82E3-structure
CE5-H82E3-sds
MBS-C014 Human ActiveMax® Human CEACAM-5 / CD66e μBeads, premium grade (for cells)
SCCHO-ATP081 Human CHO/Human CEACAM5 Stable Cell Line Development Service
CE5-H52H8 Human Human CEACAM-5 / CD66e (499-685) Protein, His Tag (MALS verified)
CE5-H52H8-structure
CHEK-ATP083 Human HEK293/Human CEACAM5 Stable Cell Line
CE5-C5257 Cynomolgus Cynomolgus CEACAM-5 / CD66e Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
CE5-C5257-structure
CE5-C5257-sds
CE5-H5259 Human Human CEACAM-5 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
CE5-H5259-structure
CE5-H5259-sds
CE5-C82E6 Cynomolgus Biotinylated Cynomolgus CEACAM-5 / CD66e Protein, His,Avitag™ (MALS verified)
CE5-C82E6-structure
CE5-C82E6-sds
CE5-H82F6 Human Biotinylated Human CEACAM-5 / CD66e Protein, Fc,Avitag™, premium grade
CE5-H82F6-structure
CE5-H82F6-sds
CE5-HF255 Human FITC-Labeled Human CEACAM-5 / CD66e Protein, Fc Tag
CE5-HF255-structure
CE5-HF255-sds
CE5-C52H5 Cynomolgus Cynomolgus CEACAM-5 / CD66e Protein, His Tag (MALS verified)
CE5-C52H5-structure
CE5-C52H5-sds
CE5-H5253 Human Human CEACAM-5 Protein, Fc Tag (HPLC verified)
CE5-H5253-structure
CE5-H5253-sds
CE5-H5253-hplc
CE5-M52H3 Mouse Mouse CEACAM-5 Protein, His Tag
CE5-M52H3-structure
CE5-M52H3-sds
CE5-M5253 Mouse Mouse CEACAM-5 Protein, Fc Tag (MALS verified)
CE5-M5253-structure
CE5-M5253-sds
CE5-HF254 Human FITC-Labeled Human CEACAM-5 / CD66e Protein, His Tag (MALS verified)
CE5-HF254-structure
CE5-HF254-sds
CE5-H82E0 Human Biotinylated Human CEACAM-5 / CD66e Protein, His,Avitag™ (MALS verified)
CE5-H82E0-structure
CE5-H82E0-sds
CE5-H5226 Human Human CEACAM-5 / CD66e Protein, His Tag (MALS verified)
CE5-H5226-structure
CE5-H5226-sds
ACRO Quality

Part of Bioactivity data

CHEK-ATP083-Cell-based assay
 CEACAM-5 FACS

Expression analysis of human CEACAM5 on HEK293/Human CEACAM5 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human CEACAM5 Stable Cell Line or negative control cell using PE-labeled anti-human CEACAM5 antibody.

CE5-H82E0-SPR
 CEACAM-5 SPR

Anti-CEACAM-5 (labetuzumab) Antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Human CEACAM-5, His,Avitag (Cat. No. CE5-H82E0) with an affinity constant of 12.1 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CE5-H5226-SPR
 CEACAM-5 SPR

Anti-CEACAM-5 (labetuzumab) Antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CEACAM-5, His Tag (Cat. No. CE5-H5226) with an affinity constant of 8.41 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name

CEACAM-5,CD66e,CEA,Meconium antigen 100

Background

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is also Carcinoembryonic antigen (CEA), Meconium antigen 100, CD antigen CD66e, CEACAM5 belongs to the immunoglobulin superfamily and CEA family. CEACAM5 contains seven Ig-like (immunoglobulin-like) domains. CEACAM5 is homodimer protein which binding of E.coli Dr adhesins leads to dissociation of the homodimer. CEACAM5 is cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. CEACAM5 is receptor for E.coli Dr adhesins.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tusamitamab Ravtansine SAR-408701; IBI-126 Phase 3 Clinical Immunogen Inc Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
SGM-101 SGM-101 Phase 3 Clinical Surgimab Sas Intestinal Neoplasms; Rectal Neoplasms; Gastrointestinal Diseases; Colonic Neoplasms; Pancreatic Neoplasms; Brain Diseases; Brain Neoplasms; Colorectal Neoplasms; Colonic Diseases; Brain metastases; Gastrointestinal Neoplasms; Intestinal Diseases Details
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) CVAC-301; CV-301 Phase 2 Clinical Therion Biologics Ovarian Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Solid tumours; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Melanoma Details
NEO-201 NEO-201 Phase 2 Clinical Precision Biologics Inc, National Cancer Institute Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Anti-CEA CAR T cell therapy (Shanghai GeneChem) Phase 2 Clinical Shanghai Genechem Co Ltd, The First Affiliated Hospital of Air Force Medical University Liver Neoplasms; Colorectal Neoplasms Details
LM-24C5 LM-24C5 Phase 2 Clinical LaNova Medicines Ltd Solid tumours; Neoplasms Details
MFE-23-CD3z T cell therapy (Cancer Research Technology) Phase 1 Clinical Cancer Research Technology Neoplasms Details
Cergutuzumab amunaleukin RG-7813; RO-6895882 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
EBC-129 EBC-129; EBC129 Phase 1 Clinical Experimental Drug Development Centre Solid tumours Details
M-9140 M-9140; M9140 Phase 1 Clinical Merck KGaA, Darmstadt, Germany Solid tumours; Colorectal Neoplasms Details
Tusamitamab Ravtansine SAR-408701; IBI-126 Phase 3 Clinical Immunogen Inc Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
SGM-101 SGM-101 Phase 3 Clinical Surgimab Sas Intestinal Neoplasms; Rectal Neoplasms; Gastrointestinal Diseases; Colonic Neoplasms; Pancreatic Neoplasms; Brain Diseases; Brain Neoplasms; Colorectal Neoplasms; Colonic Diseases; Brain metastases; Gastrointestinal Neoplasms; Intestinal Diseases Details
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) CVAC-301; CV-301 Phase 2 Clinical Therion Biologics Ovarian Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Solid tumours; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Melanoma Details
NEO-201 NEO-201 Phase 2 Clinical Precision Biologics Inc, National Cancer Institute Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Anti-CEA CAR T cell therapy (Shanghai GeneChem) Phase 2 Clinical Shanghai Genechem Co Ltd, The First Affiliated Hospital of Air Force Medical University Liver Neoplasms; Colorectal Neoplasms Details
LM-24C5 LM-24C5 Phase 2 Clinical LaNova Medicines Ltd Solid tumours; Neoplasms Details
MFE-23-CD3z T cell therapy (Cancer Research Technology) Phase 1 Clinical Cancer Research Technology Neoplasms Details
Cergutuzumab amunaleukin RG-7813; RO-6895882 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
EBC-129 EBC-129; EBC129 Phase 1 Clinical Experimental Drug Development Centre Solid tumours Details
M-9140 M-9140; M9140 Phase 1 Clinical Merck KGaA, Darmstadt, Germany Solid tumours; Colorectal Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message